Madrigal Pharmaceuticals
MDGL
305 hedge funds and large institutions have $7.13B invested in Madrigal Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 107 increasing their positions, 110 reducing their positions, and 51 closing their positions.
89% more call options, than puts
Call options by funds: $294M | Put options by funds: $155M
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
3% less repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 110
1.32% less ownership
Funds ownership: 107.4% → 106.08% (-1.3%)
5% less funds holding
Funds holding: 321 → 305 (-16)
9% less capital invested
Capital invested by funds: $7.85B → $7.13B (-$719M)
25% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$61.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$55M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$54.9M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$129M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$61.6M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$47M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$43.9M |
| 5 |
Morgan Stanley
New York
|
-$40.8M |
MDGL Hedge Fund Activity: Q2 2025 in Review
305 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2025, worth a combined $7.13B — down 9.2% from $7.85B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of MDGL and 38 opened new positions — a net loss of 13 holders — while 110 trimmed existing stakes and 107 added.
The largest buyer was Citadel Advisors, adding an estimated $61.5M. The largest seller was Holocene Advisors, exiting entirely with an estimated $129M sold.
- 305 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2025, down from 321 in Q1 2025.
- Funds reported $7.13B of Madrigal Pharmaceuticals stock for Q2 2025, down 9.2% quarter-over-quarter.
- 38 funds opened new Madrigal Pharmaceuticals positions in Q2 2025 and 51 closed out, a net change of -13 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $61.5M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2025 was Holocene Advisors, an estimated $129M sold.
Based on aggregated 13F filings for Q2 2025.